Background/Aims: The generic quality of life KINDL-R -questionnaire is validated for use in children/adolescents ≤16 years. The aim of this cross-sectional investigation was to modify the KINDL-R questionnaire for use in adults and to validate its psychometric properties. Methods: Five items of the KINDL-R questionnaire were adapted and the newly developed KINDL-A(dult) questionnaire administered to 255 patients with hereditary and acquired bleeding disorders (mean age 53 years). Its internal consistency and convergent and divergent construct validity were investigated and confirmatory factor analysis was used to evaluate the latent factor structure. Results: The KINDL-A questionnaire showed satisfactory reliability, varying construct validity, but inconclusive factor structure. The KINDL-AB(rief) was developed by removing half of the items and combining 2 sub-axes. This led to factor loadings between 0.62 and 0.91 and increased overall fit (Goodness of fit > 0.8 and Root Mean Square Error of Approximation, RMSEA, < 0.08). Results were validated in 966 healthy blood donors (mean age 38 years). In this group, the KINDL-AB questionnaire showed factor loadings between 0.43 and 0.77, Goodness of fit > 0.95 and RMSEA < 0.05. Conclusions: The new KINDL-AB suggests sufficient to good psychometric properties in adult patients with hereditary and acquired bleeding disorders.

Keywords:
Quality of life, Hereditary bleeding disorder, Transition, KINDL-R questionnaire
1.
Franchini M, Mannucci PM: Hemophilia A in the third millennium. Blood Rev 2013; 27: 179–184.
2.
Gringeri A, Mantovani L, Mackensen SV: Quality of life assessment in clinical practice in haemophilia treatment. Haemophilia 2006; 12: 22–29.
3.
Nowak-Göttl U, Clausnizer H, Kowalski D, Limperger V, Krümpel A, Shneyder M, et al: Health-related quality of life in children, adolescents and adults with hereditary and acquired bleeding disorders. Blood Cells Mol Dis 2017; 67: 96–101.
4.
Bullinger M, von Mackensen S: Quality of life assessment in haemophilia. Haemophilia 2004; 10: 9–16.
5.
Miners A, Sabin C, Tolley K, Jenkinson C, Kind P, Lee C: Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 378–385.
6.
Siboni SM, Mannucci PM, Gringeri A, Franchini M, Tagliaferri A, Ferretti M, et al; Italian Association of Haemophilia Centres (AICE): Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost 2009; 7: 780–786.
7.
Rosendaal FR, Smit C, Varekamp I, Bröcker-Vriends AH, van Dijck H, Suurmeijer TP, et al: Modern haemophilia treatment: medical improvements and quality of life. J Intern Med 1990; 228: 633–640.
8.
Ravens-Sieberer U, Erhart M, Wille N, Bullinger M; BELLA study group: Health-related quality of life in children and adolescents in Germany: results of the BELLA study. Eur Child Adolesc Psychiatry 2008; 17: 148–156.
9.
Serra-Sutton V, Ferrer M, Rajmil L, Tebé C, Simeoni MC, Ravens-Sieberer U: Population norms and cut-off-points for suboptimal health related quality of life in two generic measures for adolescents: the Spanish VSP-A and KINDL-R. Health Qual Life Outcomes 2009; 7: 35.
10.
Milde-Busch A, Heinrich S, Thomas S, Kühnlein A, Radon K, Straube A, et al: Quality of life in adolescents with headache: results from a population-based survey. Cephalagia 2010; 30: 713–721.
11.
de Wit M, Delemarre-van de Waal HA, Pouwer F, Gemke RJ, Snoek FJ: Monitoring health related quality of life in adolescents with diabetes: a review of measures. Arch Dis Child 2007; 92: 434–439.
12.
Hullmann SE, Ryan JL, Ramsey RR, Chaney JM, Mullins LL: Measures of general pediatric quality of life: Child Health Questionnaire (CHQ), DISABKIDS Chronic Generic Measure (DCGM), KINDL-R, Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales, and Quality of My Life Questionnaire (QoML). Arthritis Care Res (Hoboken) 2011; 63(suppl 11):S420–S430.
13.
Khair K, Littley A, Will A, von Mackensen S: The impact of sport on children with haemophilia. Haemophilia 2012; 18: 898–905.
14.
Henrard S, Devleesschauwer B, Beutels P, Callens M, De Smet F, Hermans C, Speybroeck N: The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis 2014; 9: 39.
15.
Floyd FJ, Widaman KF: Factor analysis in the development and refinement of clinical assessment instruments. Psychol Assess 1995; 7: 286–299.
16.
Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
17.
EuroQol Group: EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.
18.
Rosseel Y: lavaan: an R package for structural equation modeling. J Stat Softw 2012; 48: 1–36.
19.
Byrne BM: Structural Equation Modeling with EQS and EQS/Windows. Thousand Oaks, SAGE Publications, 1994.
20.
Fan X, Thompson B, Wang L: Effects of sample size, estimation method, and model specification on structural equation modeling fit indexes. Struct Equation Model 1999; 6: 56–83.
21.
MacCallum RC, Browne MW, Sugawara HM: Power analysis and determination of sample size for covariance structure modeling. Psychol Methods 1996; 1: 130–149.
22.
Matsunaga M: How to factor-analyze your data right Do’s Don’ts and How-To’s. Int J Psychol Res 2010; 3: 97–110.
23.
De Vet HCW, Terwee CB, Mokkink LB, Knol DL: Measurement in Medicine: A Practical Guide. New York, Cambridge University Press, 2011.
24.
Evans JD: Straightforward Statistics for the Behavioral Sciences. Pacific Grove, Brooks/Cole Publishing, 1996.
25.
Nunnally JC, Bernstein ICH: Psychometric Theory (ed 3). London, McGraw-Hill, Inc 1994.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.